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Long-Term Outcomes After Management of
Restenosis or Thrombosis of Drug-Eluting Stents
Gregory J. Mishkel, MD, FACC,*†‡ Anna L. Moore, MPH,† Steve Markwell, MA,‡
M. Coleman Shelton,† Marc E. Shelton, MD, FACC,*†‡
Springfield, Illinois
Objectives The purpose of this study was to examine the outcomes of patients who developed coronary in-stent restenosis
(ISR) or stent thrombosis (STH) inside drug-eluting stents (DES).
Background Drug-eluting stents have markedly reduced the incidence of restenosis. However, when restenosis occurs within
a DES, its optimal management remains unclear.
Methods We retrospectively analyzed clinical and angiographic data from 92 patients who underwent revascularization
for ISR (n  84) or STH (n  8) within a DES at our institution. Regular follow-ups were available up to 2 years.
We recorded the occurrence of major adverse cardiac events (MACE), defined as deaths from all causes, myo-
cardial infarction (MI), or target lesion revascularization (TLR), among patients treated by the “DES sandwich”
technique or by other treatment methods.
Results In-hospital MACE included 1 periprocedural MI and 2 deaths. Over a mean follow-up of 15  6 months, the over-
all rates of death, MI, and TLR were 8.7%, 2.2%, and 30.6%, respectively. By actuarial analysis, the 12-month
TLR and MACE rates were 28.2% and 42.9%, respectively.
Conclusions Current treatments of ISR or STH in DES are associated with a high long-term rate of MACE. (J Am Coll Cardiol
2007;49:181–4) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.049s
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aespite the marked decrease in major adverse cardiovascular
vents (MACE) attributable to drug-eluting stents (DES),
n-stent restenosis (ISR) and stent thrombosis (STH) remain
mportant clinical challenges. The “stent sandwich” technique
stent within a stent) has been applied with mixed results for
estenosis after bare-metal stenting (BMS) (1–4). Little infor-
ation is available, however, regarding the long-term results of
his technique for ISR or STH of DES. We present our
bservations in consecutive patients who developed one of
hese adverse events after DES implantation.
atient Population and Methods
e identified 92 consecutive patients who developed ISR
n  84) or STH (n  8) after DES implantation. All
atients had received aspirin, 325 mg, before the initial
rocedure, followed by 75 mg daily indefinitely, along
ith clopidogrel or ticlopidine for 6 months.
rom the *Prairie Heart Institute at St. John’s Hospital, Springfield, Illinois; †Prairie
ducation & Research Cooperative, Springfield, Illinois; and the ‡Southern Illinois
niversity School of Medicine, Springfield, Illinois. This study was funded, in part,
y grants from Cordis Corporation, a Johnson & Johnson company, and from Boston
cientific. Dr. Mishkel has received consulting income from Cordis/Johnson &
ohnson, Boston Scientific, Guidant/Abbott, and Medtronic.1
Manuscript received February 1, 2006; revised manuscript received August 10,
006, accepted August 15, 2006.The “homo-stent sandwich” technique consisted of re-
tenting with the same DES, “hetero-stent sandwich” with
different DES, and “other” techniques included balloon
ngioplasty, insertion of a BMS, or brachytherapy. In-stent
estenosis was defined as a 50% diameter stenosis within
he first DES, or within 5 mm of its edges. The morphology
f restenotic lesions has been described elsewhere (5). Major
dverse cardiac events included death from all causes,
yocardial infarction (MI), or target lesion revasculariza-
ion (TLR). Myocardial infarction was defined as chest pain
ccompanied by new electrocardiographic changes consis-
ent with ischemia and a creatine kinase (CK)-MB concen-
ration 3-fold the upper normal limit. Target lesion
evascularization was defined as re-intervention on the
tented segment for chest pain or 70% stenosis on
ollow-up angiogram. Stent thrombosis was defined as an
ntraluminal filling defect with contrast staining on 3 sides,
epresenting total or partial stent occlusion, present at the
ime of a clinically driven, repeat angiography. Patients were
ollowed clinically at 6 months, and 1 and 2 years.
tatistical analyses. Discrete variables are reported as per-
entages and continuous variables as means SD. Chi-square
r Fisher exact tests were used to compare discrete variables
nd Student t tests for continuous variables. Actuarial 6- and
2-month rates of MACE were examined by the Kaplan-
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were considered statistically
significant.
Results
Between May 2003 and Decem-
ber 2004, among 4,912 lesions
treated with DES, 108 (92 pa-
tients) required clinically driven re-
vascularization for ISR (n  103)
or STH (n  8), including 64
lesions treated by homo-stent (61
sirolimus and 3 paclitaxel), and 22
hetero-stent (19 paclitaxel in
sirolimus and 3 sirolimus in pacli-
taxel) sandwich. The other 22 le-
sions were treated with balloon
angioplasty (n  19), BMS (n 
), or brachytherapy (n  1). Within the study period, the
linical need for repeat revascularization within was only 2.2%.
he clinical characteristics of the 92 patients who developed
SR/STH and those of 2,813 patients who remained ISR/
TH-free are compared in Table 1. Patients who developed
SR/STH were more likely to be persons with diabetes, hyper-
ensive and hypercholesterolemic, more often had histories of MI,
rior coronary artery bypass graft surgery, or percutaneous coro-
ary intervention (PCI), and had a lower prevalence of non–ST-
Abbreviations
and Acronyms
BMS  bare-metal
stent(ing)
DES  drug-eluting stents
ISR  in-stent restenosis
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
STH  stent thrombosis
TLR  target lesion
revascularization
linical Characteristics of 92 Patients Who DevelopedSR/STH in DES Versu Those of 2,813 Patients Whoemained F ee of ISR/S H in DES (No ISR/STH)
Table 1
Clinical Characteristics of 92 Patients Who Developed
ISR/STH in DES Versus Those of 2,813 Patients Who
Remained Free of ISR/STH in DES (No ISR/STH)
ISR/STH
(n  92)
No ISR/STH
(n  2,813) p Value
Age 65 yrs 50 (54.3) 1,564 (55.6) NS
Men 64 (69.6) 1,758 (62.5) NS
Diabetes 39 (42.4) 821 (29.2) 0.006
Active smoker 16 (17.4) 670 (23.8) NS
Hypertension 85 (92.4) 2,143 (76.2) 0.001
Hypercholesterolemia 86 (93.5) 2,210 (78.6) 0.001
Renal insufficiency 2 (2.2) 85 (3.0) NS
History of congestive heart failure 11 (12.0) 252 (9.0) NS
Cerebrovascular disease 14 (15.2) 351 (12.5) NS
Peripheral vascular disease 13 (14.1) 355 (12.6) NS
Prior myocardial infarction 51 (55.4) 775 (27.6) 0.001
Prior coronary artery bypass 35 (38.0) 707 (25.1) 0.005
Prior percutaneous coronary
intervention
92 (100) 859 (30.5) 0.001
ST–segment elevation myocardial
infarction at presentation
7 (7.6) 233 (8.3) NS
Non–ST-segment elevation myocardial
infarction at presentation
3 (3.3) 421 (15.0) 0.003
Unstable angina at presentation 42 (45.7) 874 (31.1) 0.004
Stable angina at presentation 33 (35.9) 963 (34.3) NS
Silent ischemia at presentation 7 (7.6) 320 (11.4) NS
Multivessel coronary disease 54 (58.7) 1,850 (65.8) NS
Left ventricular ejection fraction 40% 13 (14.1) 340 (12.9) NSr
alues indicate numbers (%) of patients in corresponding group.
DES  drug-eluting stents; ISR  in-stent restenosis; STH  stent thrombosis.egment elevation myocardial infarction (STEMI) and higher
revalence of unstable angina at presentation.
The clinical and angiographic characteristics, and the
ndications for repeat PCI among the 92 patients, and
mong the 3 treatment subgroups, are shown in Table 2.
xcept for a higher prevalence of prior congestive heart
ailure in the “Others,” these subgroups were similar. Three
atients required 2 procedures during separate admissions
or DES ISR in separate lesions. Clopidogrel was admin-
stered for an average of 14.6  6.1 months.
Stent thrombosis occurred in 8 patients and resulted in
TEMI in 6. Five patients had early STH within 30 days of
mplantation, and 3 had late STH after 180 days. Among
hese 6 STEMI patients, 1 died of MI at 212 days and 1 had
ecurrent STH at 71 days of follow-up. Two non-STEMI
atients who had undergone repeat PCI for STH that
ccurred within 30 days of initial DES placement died in
enal failure and cardiogenic shock, at 4 and 8 days,
espectively, after the stent sandwich procedure.
Outcome data were available for 91 patients (99%). Over a
ean follow-up of 15.0  6.0 months, the overall rates of
eath, MI, and TLR were 8.7%, 2.2%, and 30.6%, respec-
ively. The cumulative rates of in-hospital, 6-month, and
2-month adverse clinical events are summarized in Table 3.
ecurrent restenosis recurred in 28 patients (30.4%) and 33
esions (30.6%). Of 6 patients who died after hospital dis-
harge, 3 died of MI at 19, 105, and 212 days, respectively, 1
ied of end-stage heart failure at 718 days, 1 died of respiratory
ailure at 511 days, and 1 died of unknown cause at 219 days
f follow-up. Outcomes among treatment subgroups were
tatistically similar, although the “hetero-stent” treatment
roup tended to have lower MACE rates and need for repeat
evascularization at 12 months.
iscussion
lthough stent sandwich has mostly replaced brachyther-
py, there is a paucity of data regarding treatments and
utcomes in patients with DES restenosis. In contrast with
he disappointing results of the RIBS (Restenosis Intra-
tent: Balloon angioplasty versus elective Stenting) study,
here BMS ISR was treated with another BMS, the stent
andwich technique was superior to balloon angioplasty for
he treatment of BMS ISR in the ISAR-DESIRE
Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs.
alloon Angioplasty for Prevention of Recurrences in Pa-
ients With Coronary In-Stent Restenosis) study (6), and
ther studies have shown promising results with DES
mplanted for BMS ISR (3,4,7–9). Ours is the first report of
he “real-world” performance of stent sandwich in a con-
ecutive series of patients with DES ISR.
In the BMS era, STH was a rare event. It is noteworthy
hat 8 patients (8.7% of the study population) presented
ith STH, and that 4 (66.7%) either died or suffered
ecurrence of STH. This observation highlights recent
eports suggesting that DES might be associated with a
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elayed endothelization, or positive remodeling (10–15).
egardless of the underlying mechanism, it should be
mphasized that DES patients who experience thrombotic
vents are probably at higher risk of recurrent STH, with its
atastrophic consequences, than ISR.
The major adverse cardiovascular event rate, including
verall mortality, was high in this population and could not be
ttributed to small vessel size (data not shown). However,
linical and Angiographic Characteristics of Overall Population and
Table 2 Clinical and Angiographic Characteristics of Overall Po
Variables
Clinical
All
(n  92)
Age, yrs (mean  SD) 65 12
Men 64 (69.6)
Diabetes 39 (42.4)
Active smoker 16 (17.4)
Hypertension 85 (92.4)
Hypercholesterolemia 86 (93.5)
Renal insufficiency 2 (2.2)
History of:
Congestive heart failure 11 (12.0)
Cerebrovascular disease 14 (15.2)
Peripheral vascular disease 13 (14.1)
Myocardial infarction 51 (55.4)
Coronary artery bypass graft 35 (38.0)
ST-segment elevation MI at presentation 7 (7.6)
Multivessel coronary disease 54 (58.7)
Left ventricular ejection fraction, % (mean  SD) 51 12
Indications for repeat PCI
MI 10 (10.9)
Angina 75 (81.5)
Stable 33 (35.9)
Unstable 42 (45.7)
Silent ischemia 7 (7.6)
Angiographic (n  108)
Reference vessel diameter, mm (mean  SD) 2.7 0.7
Lesion length, mm (mean  SD) 20.9 11.1
Pre-stenosis, % (mean  SD) 84.9 12.3
Post-stenosis, % (mean  SD) 2.0 3.7
Target vessel
Left anterior descending 38 (35.2)
Right coronary artery 32 (29.6)
Left circumflex artery 17 (15.7)
Left main artery 3 (2.8)
Graft 18 (16.7)
Lesion morphology
Focal 44 (40.7)
Diffuse 20 (18.5)
Proliferative 1 (0.9)
Occlusion 9 (8.3)
Edge (5 mm proximal/distal) 34 (31.5)
nless specified otherwise, values indicate number (%) of patients or lesions in corresponding gro
MI  myocardial infarction; PCI  percutaneous coronary intervention.atients who had MACE during follow-up had a higher troportion of saphenous vein graft and a lower percentage of
dge restenosis. Tentative explanations for the high MACE
ate after stent sandwich include: 1) enhanced allergic or
nflammatory responses to the polymer or the drug; 2) exces-
ive intimal hyperplastic response inadequately blocked by the
rug or amount of drug delivered; 3) insufficient expansion or
mproper placement of the stent; and 4) individual predispo-
ition to exaggerated neointimal hyperplasia.
Although the difference was not statistically significant,
ach Treatment Group
ion and of Each Treatment Group
Patients
o-Stents
 59)
Hetero-Stents
(n  18)
Others
(n  15) p Value*
6 11 65 15 59 10 NS
(78.0) 10 (55.6) 8 (53.3) NS
(37.3) 7 (38.9) 10 (66.7) NS
(11.9) 5 (27.8) 4 (26.7) NS
(93.2) 16 (88.9) 14 (93.3) NS
(91.5) 17 (94.4) 15 (100) NS
0 1 (5.6) 1 (6.7) NS
(5.1) 1 (5.6) 7 (46.7) 0.001
(15.3) 2 (11.1) 3 (20.0) NS
(15.3) 1 (5.6) 3 (20.0) NS
(55.9) 11 (61.1) 7 (46.7) NS
(39.0) 7 (38.9) 5 (33.3) NS
(5.1) 2 (11.1) 2 (13.3) NS
(54.2) 14 (77.8) 8 (53.3) NS
3 10 49 14 50 13 NS
(10.2) 2 (11.1) 2 (13.3) NS
(81.4) 16 (88.9) 11 (73.4) NS
(40.7) 5 (27.8) 4 (26.7) NS
(40.7) 11 (61.1) 7 (46.7) NS
(8.5) 0 2 (13.3) NS
Lesions
 64) (n  22) (n  22)
.6 0.6 2.9 0.9 2.6 0.7 NS
.9 10.6 20.4 12.9 21.6 10.6 NS
.3 12.1 83.8 11.7 87.4 13.4 NS
.1 3.9 1.3 2.2 2.2 4.1 NS
4 (37.5) 5 (22.7) 9 (40.9) NS
8 (28.1) 8 (36.4) 6 (27.3) NS
9 (14.1) 6 (27.3) 2 (9.1) NS
2 (3.1) 0 1 (4.6) NS
1 (17.2) 3 (13.6) 4 (18.2) NS
4 (37.5) 11 (50.0) 9 (40.9) NS
1 (17.2) 5 (22.7) 4 (18.2) NS
0 0 1 (4.6) NS
4 (6.2) 2 (9.1) 3 (13.6) NS
5 (39.1) 4 (18.2) 5 (22.7) NS
e p values are for comparisons among the 3 treatment groups.of E
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his might be explained by differences in the tissular
esponse to the different DES, such that an initially poor
esponse to 1 drug would be a signal to implant a DES that
elivers another drug with different mechanisms of action.
inally, given the relatively high MACE rate in the DES
SR population, coronary artery bypass surgery should be
onsidered as a viable treatment alternative for complex
ES restenosis.
tudy limitations. Our observations were limited to the
xperience of a single medical center. The absence of random-
zation to treatment strategy and retrospective design are other
imitations of this study, which might have been underpowered
o detect differences among treatment strategies.
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